Proteomic landscape subtype and clinical prognosis of patients with the cognitive impairment by Japanese encephalitis infection
-
Published:2022-04-04
Issue:1
Volume:19
Page:
-
ISSN:1742-2094
-
Container-title:Journal of Neuroinflammation
-
language:en
-
Short-container-title:J Neuroinflammation
Author:
Yin Rong, Yang Linpeng, Hao Ying, Yang Zhiqi, Lu Tao, Jin Wanjun, Dan Meiling, Peng Liang, Zhang Yingjie, Wei Yaxuan, Li Rong, Ma Huiping, Shi Yuanyuan, Fan PengchengORCID
Abstract
Abstract
Background
Cognitive impairment is one of the primary sequelae affecting the quality of life of patients with Japanese encephalitis (JE). The clinical treatment is mainly focused on life support, lacking of targeted treatment strategy.
Methods
A cerebrospinal fluid (CSF) proteomic profiling study was performed including 26 patients with JE in Gansu province of China from June 2017 to October 2018 and 33 other concurrent hospitalized patients who were excluded central nervous system (CNS) organic or CNS infection diseases. The clinical and proteomics data of patients with JE were undergoing combined analysis for the first time.
Results
Two subtypes of JE associated with significantly different prognoses were identified. Compared to JE1, the JE2 subtype is associated with lower overall survival rate and a higher risk of cognitive impairment. The percentages of neutrophils (N%), lymphocyte (L%), and monocytes (M%) decreased in JE2 significantly.
Conclusions
The differences in proteomic landscape between JE subgroups have specificity for the prognosis of cognitive impairment. The data also provided some potential target proteins for treatment of cognitive impairments caused by JE.
Trial registration ChiCTR, ChiCTR2000030499. Registered 1st June 2017, http://www.medresman.org.cn/pub/cn/proj/projectshow.aspx?proj=6333
Funder
young scientists fund biosafety project foundation
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Neurology,Immunology,General Neuroscience
Reference35 articles.
1. Turtle L, Solomon T. Japanese encephalitis—the prospects for new treatments. Nat Rev Neurol. 2018;14:298–313. 2. Im J, Balasubramanian R, Yastini NW, Suwarba IGN, Andayani AR, Bura V, Jeon HJ, Clemens JD, Marks F. Protecting children against Japanese encephalitis in Bali, Indonesia. Lancet. 2018;391:2500–1. 3. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, Ginsburg AS. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011;89(766–774):774A-774E. 4. Heffelfinger JD, Li X, Batmunkh N, Grabovac V, Diorditsa S, Liyanage JB, Pattamadilok S, Bahl S, Vannice KS, Hyde TB, et al. Japanese encephalitis surveillance and immunization—Asia and Western Pacific Regions, 2016. MMWR Morb Mortal Wkly Rep. 2017;66:579–83. 5. Mukherjee S, Singh N, Sengupta N, Fatima M, Seth P, Mahadevan A, Shankar SK, Bhattacharyya A, Basu A. Japanese encephalitis virus induces human neural stem/progenitor cell death by elevating GRP78, PHB and hnRNPC through ER stress. Cell Death Dis. 2017;8:e2556.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|